MIBG Scanning for Lewy Body Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses a special radioactive drug and a heart scan to help identify Lewy Body Disease in people with certain neurological symptoms. The scan checks how well the heart absorbs the drug to find early signs of this brain disorder.
Will I have to stop taking my current medications?
The trial requires that your medication regimen has been stable for the previous four weeks, and you must not be taking certain medications that could affect the scan results. It's best to discuss your current medications with the study team to see if any changes are needed.
Is MIBG scanning safe for humans?
How is the treatment 123I-MIBG scintigraphy unique for Lewy Body Disease?
123I-MIBG scintigraphy is unique because it helps in diagnosing Lewy Body Disease by imaging nerve function in the heart, which is often reduced in these conditions. This imaging technique is particularly useful for distinguishing Lewy Body Disease from other similar disorders like Parkinson's disease and Alzheimer's disease.12346
What data supports the effectiveness of the treatment 123I-MIBG scintigraphy for Lewy Body Disease?
Who Is on the Research Team?
Bradley Boeve, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for individuals with certain neurological disorders like Lewy Body Disease, Parkinson's, or dementia. Participants need a caregiver present at least 20 hours per week and must have stable medication use without severe medical conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo myocardial 123I-MIBG scintigraphy imaging to assess neurologic and cardiac function
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- 123I-MIBG scintigraphy
- meta-iodobenzylguanidine (MIBG) (123I)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor